UPMC Univ, Sorbonne Université, Dpt of Life Science, Paris, France.
Centre de Recherche des Cordeliers, INSERM, Paris, France.
Hum Mutat. 2019 May;40(5):516-524. doi: 10.1002/humu.23717. Epub 2019 Mar 28.
The 1,000 genome project, the Exome Aggregation Consortium (ExAC) or the Genome Aggregation database (gnomAD) datasets, were developed to provide large-scale reference data of genetic variations for various populations to filter out common benign variants and identify rare variants of clinical importance based on their frequency in the human population. Using a TP53 repository of 80,000 cancer variants, as well as TP53 variants from multiple cancer genome projects, we have defined a set of certified oncogenic TP53 variants. This specific set has been independently validated by functional and in silico predictive analysis. Here we show that a significant number of these variants are included in gnomAD and ExAC. Most of them correspond to TP53 hotspot variants occurring as somatic and germline events in human cancer. Similarly, disease-associated variants for five other tumor suppressor genes, including BRCA1, BRCA2, APC, PTEN, and MLH1, have also been identified. This study demonstrates that germline TP53 variants in the human population are more frequent than previously thought. Furthermore, population databases such as gnomAD or ExAC must be used with caution and need to be annotated for the presence of oncogenic variants to improve their clinical utility.
1000 基因组计划、外显子组聚合联盟 (ExAC) 或基因组聚合数据库 (gnomAD) 数据集的开发旨在为各种人群提供大规模的遗传变异参考数据,以过滤掉常见的良性变异,并根据其在人群中的频率识别具有临床重要性的罕见变异。我们使用了一个包含 80000 个癌症变异的 TP53 存储库,以及来自多个癌症基因组计划的 TP53 变异,定义了一组经过认证的致癌性 TP53 变异。这一特定集合已经通过功能和计算预测分析进行了独立验证。在这里,我们表明这些变体中有相当数量的变体包含在 gnomAD 和 ExAC 中。它们中的大多数对应于 TP53 热点变异,作为体细胞和种系事件发生在人类癌症中。同样,其他五个肿瘤抑制基因,包括 BRCA1、BRCA2、APC、PTEN 和 MLH1 的疾病相关变异也已被确定。这项研究表明,人类群体中的种系 TP53 变异比以前认为的更为常见。此外,人群数据库,如 gnomAD 或 ExAC,必须谨慎使用,并需要对致癌变异的存在进行注释,以提高其临床实用性。